Last reviewed · How we verify
nivolumab, docetaxel, cisplatin Group
nivolumab, docetaxel, cisplatin Group is a Small molecule drug developed by Myung-Ju Ahn. It is currently in Phase 2 development.
At a glance
| Generic name | nivolumab, docetaxel, cisplatin Group |
|---|---|
| Sponsor | Myung-Ju Ahn |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Benefit Population Atlas of nICT Versus nCT for LAGC
- The Prospective Non-randomized Case-control Study From Real-world Lung Cancer Patients
- Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy (PHASE2)
- Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma (PHASE2)
- PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nivolumab, docetaxel, cisplatin Group CI brief — competitive landscape report
- nivolumab, docetaxel, cisplatin Group updates RSS · CI watch RSS
- Myung-Ju Ahn portfolio CI
Frequently asked questions about nivolumab, docetaxel, cisplatin Group
What is nivolumab, docetaxel, cisplatin Group?
nivolumab, docetaxel, cisplatin Group is a Small molecule drug developed by Myung-Ju Ahn.
Who makes nivolumab, docetaxel, cisplatin Group?
nivolumab, docetaxel, cisplatin Group is developed by Myung-Ju Ahn (see full Myung-Ju Ahn pipeline at /company/myung-ju-ahn).
What development phase is nivolumab, docetaxel, cisplatin Group in?
nivolumab, docetaxel, cisplatin Group is in Phase 2.